• Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    France Germany Italy Spain

  • Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Hungary Poland Spain

  • Study of Atezolizumab and Tiragolumab for Patients with Resectable Solid Tumors at Intermediate-High Risk of Recurrence

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Spain

  • Study of Fulvestrant and Abemaciclib for Women with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Belgium Greece Italy Poland Spain

  • Study of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Italy

  • Study on the Effects of Baricitinib in Early-Stage Rheumatoid Arthritis

    Not recruiting

    2 1 1
    Germany

  • Study of Long-term Safety and Efficacy of Fitusiran in Patients with Hemophilia A or B with or without Inhibitory Antibodies to Factor VIII or IX

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Denmark France Hungary Ireland Italy

  • Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated diseases:
    Belgium Czechia France Germany Hungary Italy +3

  • Study of HORA-PDE6B’s Safety in Retinitis Pigmentosa Patients with PDE6B Gene Mutations

    Not recruiting

    2 1 1 1
    Investigated diseases:
    France

  • Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson’s Disease Patients with Motor Fluctuations

    Not recruiting

    3 1
    Investigated diseases:
    Austria Belgium Czechia France Italy Poland +3

powered by